Details of the Drug Combinations

General Information of This Drug (ID: DMCBJSR)

Drug Name
Sunitinib   DMCBJSR
Synonyms
Sunitanib; Sunitinibum; Sutent; PDGF TK antagonist; SU 11248; SU11248; KS-5022; SU-11248; SU-11248J; SU-12662; Su-011248; Sunitinib (INN); Sunitinib (free base); Sutent (TN); N-(2-diethylaminoethyl)-5-[(Z)-(5-fluoro-2-oxo-1H-indol-3-ylidene)methyl]-2,4-dimethyl-1H-pyrrole-3-carboxamide; N-[2-(diethylamino)ethyl]-5-[(Z)-(5-fluoro-2-oxo-1,2-dihydro-3H-indol-3-ylidene)methyl]-2,4-dimethyl-1H-pyrrole-3-carboxamide; 5-(5-FLUORO-2-OXO-1,2-DIHYDRO-INDOL-3-YLIDENEMETHYL)-2,4-DIMETHYL-1H-PYRROLE-3-CARBOXYLIC ACID (2-DIETHYLAMINO-ETHYL)-AMIDE; Sunitinib (Pan-TK inhibitor)
Indication
Disease Entry ICD 11 Status REF
Acute undifferentiated leukemia N.A. Approved [1]
Chronic myelomonocytic leukemia N.A. Approved [1]
Classic Kaposi sarcoma N.A. Approved [1]
Gastrointestinal cancer 2C11 Approved [2]
Gastrointestinal stromal tumour 2B5B Approved [3]
Large granular lymphocytic leukemia 2A90.1 Approved [1]
Lung cancer 2C25.0 Approved [1]
Mast cell leukaemia 2A21.00 Approved [1]
Non-small-cell lung cancer 2C25.Y Approved [1]
Pancreatic cancer 2C10 Approved [1]
Primary myelofibrosis 2A20.2 Approved [1]
Prolymphocytic leukaemia 2A82.1 Approved [1]
Prostate adenocarcinoma N.A. Approved [1]
Refractory chronic myeloid leukaemia 2A20 Approved [1]
Salivary gland squamous cell carcinoma N.A. Approved [1]
Plexiform neurofibroma N.A. Investigative [1]
⏷ Show the Full List of Indication(s)
Therapeutic Class
Anticancer Agents
Drug Type
Small molecular drug
Structure
3D MOL 2D MOL

List of Combinatorial Drugs (CBD) Containing This Drug

27 Clinical Trial Drug Combination(s) Consisting of This drug
DrugCom Name DrugCom ID Component Drug Indication REF
Enzastaurin + Sunitinib DCER4MC Enzastaurin Metastatic Renal Cell Carcinoma [4]
Everolimus + Sunitinib DC1NW6M Everolimus Renal Cell Carcinoma [5]
Everolimus + Sunitinib DCG6XFX Everolimus Metastatic Renal Cell Carcinoma [6]
Fludeoxyglucose F 18 + Sunitinib DCQY3BG Fludeoxyglucose F 18 Kidney Neoplasms [7]
Gemcitabine + Sunitinib DCV7R5U Gemcitabine Renal Cell Carcinoma [8]
Lenalidomide + Sunitinib DCI4BXC Lenalidomide Renal Cell Carcinoma [9]
LY2835219 + Sunitinib DC39RDV LY2835219 Renal Cell Carcinoma Metastatic [10]
Sunitinib + Erlotinib DC0O0KQ Erlotinib Carcinoma, Non-Small-Cell Lung [11]
Sunitinib + Pazopanib DC3R7O5 Pazopanib Carcinoma, Renal Cell [12]
Sunitinib + Axitinib DC73CTF Axitinib Kidney Neoplasms [13]
Sunitinib + Axitinib DCATK01 Axitinib Carcinoma [14]
Sunitinib + Docetaxel DCDEV8F Docetaxel Prostate Cancer [15]
Sunitinib + Lanreotide acetate DCDTHDC Lanreotide acetate Carcinoid Tumors [16]
Sunitinib + Temsirolimus DCF44X2 Temsirolimus Metastatic Renal Cell Carcinoma [17]
Sunitinib + Cediranib DCKLCII Cediranib Sarcoma, Alveolar Soft Part [18]
Sunitinib + Docetaxel DCPKS2E Docetaxel Advanced Solid Tumors [19]
Sunitinib + Capecitabine DCUKVMF Capecitabine Advanced/Metastatic Breast Cancer [20]
Sunitinib + Capecitabine DCVMILF Capecitabine Breast Cancer [21]
Sunitinib + Carboplatin DCNGANV Carboplatin Breast Cancer [22]
Sunitinib + Regorafenib DC0I3EK Regorafenib Gastrointestinal Stromal Tumor [23]
Sunitinib + Contigoside B DCIQJHS Contigoside B Renal Cell Carcinoma [24]
Propranolol + Sunitinib DCGQX9W Propranolol Renal Cell Carcinoma [25]
Sunitinib + Carboplatin DC0WUY4 Carboplatin Small Cell Lung Cancer [26]
Sunitinib + Pazopanib DC38BKC Pazopanib Metastatic Renal Cell Carcinoma [27]
Sunitinib + Regorafenib DCH61OA Regorafenib Gastrointestinal Stromal Tumors [28]
Sunitinib + Temozolomide DCR4EQU Temozolomide Glioblastoma Multiforme [29]
Sunitinib + Cabozantinib DC7NJPE Cabozantinib Renal Cell Carcinoma [30]
------------------------------------------------------------------------------------
⏷ Show the Full List of 27 DrugCom(s)

References

1 Sunitinib FDA Label
2 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 5713).
3 The ChEMBL database in 2017. Nucleic Acids Res. 2017 Jan 4;45(D1):D945-D954.
4 ClinicalTrials.gov (NCT00709995) A Study for Participants With Metastatic Renal Cell Carcinoma
5 ClinicalTrials.gov (NCT00788060) A Phase Ib Study of Rad001 and Sutent to Treat Renal Cell Carcinoma
6 ClinicalTrials.gov (NCT01784978) Efficacy Study of Sunitinib and Everolimus (Rotational vs Sequential Arm) in Pats. With m Clear Cell Renal Cancer
7 ClinicalTrials.gov (NCT00537056) Evaluating Sunitinib Therapy in Renal Cell Carcinoma Using F-18 FDG PET/CT and DCE MRI
8 ClinicalTrials.gov (NCT00556049) Combination Sunitinib and Gemcitabine in Sarcomatoid and/or Poor-risk Patients With Metastatic Renal Cell Carcinoma
9 ClinicalTrials.gov (NCT00975806) Study of Lenalidomide in Combination With Sunitinib to Evaluate the Safety and Efficacy in Patients With Renal Cell Carcinoma
10 ClinicalTrials.gov (NCT03905889) A Study of Abemaciclib in Combination With Sunitinib in Metastatic Renal Cell Carcinoma
11 ClinicalTrials.gov (NCT00265317) A Study In Patients With Non-Small Cell Lung Cancer Testing If Erlotinib Plus SU011248 (Sunitinib) Is Better Than Erlotinib Alone
12 ClinicalTrials.gov (NCT01064310) Patient Preference Study of Pazopanib Versus Sunitinib in Advanced or Metastatic Kidney Cancer
13 ClinicalTrials.gov (NCT04669366) Treatment Patterns With Targeted Therapies In Mrcc In Sweden - A Retrospective Analysis Of Data From National Registries
14 ClinicalTrials.gov (NCT04033991) Study of Patients With Metastatic and/or Advanced Renal Cell Carcinoma, Treated With Sunitinib/Axitinib.
15 ClinicalTrials.gov (NCT00734851) Multimodality Phase II Study in Prostate Cancer
16 ClinicalTrials.gov (NCT01731925) A Study of Sunitinib Versus Placebo in Combination With Lanreotide in Patients With Progressive Advanced/Metastatic Midgut Carcinoid Tumors
17 ClinicalTrials.gov (NCT01517243) Phase II Study of Alternating Sunitinib and Temsirolimus
18 ClinicalTrials.gov (NCT01391962) Sunitinib or Cediranib for Alveolar Soft Part Sarcoma
19 ClinicalTrials.gov (NCT00712504) Study Of SU011248 In Combination With Docetaxel In Patients With Advanced Cancer
20 ClinicalTrials.gov (NCT00662025) Study Of Sunitinib With Capecitabine In Breast Cancer
21 ClinicalTrials.gov (NCT00570908) Brain Mets - Capecitabine Plus Sunitinib and WBRT
22 ClinicalTrials.gov (NCT00887575) Neoadjuvant Sunitinib With Paclitaxel/Carboplatin in Patients With Triple-Negative Breast Cancer
23 ClinicalTrials.gov (NCT02164240) Phase Ib Study of SUnitinib Alternating With REgorafenib in Patients With Metastatic and/or Unresectable GIST
24 ClinicalTrials.gov (NCT02446795) Isoquercetin as an Adjunct Therapy in Patients With Kidney Cancer Receiving First-line Sunitinib: a Phase I/II Trial
25 ClinicalTrials.gov (NCT03323710) Study of Propranolol Plus Sunitinib in First-line Treatment of Metastatic Renal Cell Carcinoma
26 ClinicalTrials.gov (NCT00695292) Irinotecan, Carboplatin, and Sunitinib in First Line Extensive-Stage Small Cell Lung Cancer
27 ClinicalTrials.gov (NCT02959554) Study in Which Therapy is Either Switched to Nivolumab After 3 Months of Treatment or Therapy is Continued With a Tyrosine Kinase Inhibitor in Patients With Metastatic Renal Cell Carcinoma (RCC) and Disease Control
28 ClinicalTrials.gov (NCT05366816) ctDNA-Guided Sunitinib And Regorafenib Therapy for GIST
29 ClinicalTrials.gov (NCT02928575) Combining Sunitinib, Temozolomide and Radiation to Treat Patients Diagnosed With Glioblastoma
30 ClinicalTrials.gov (NCT03729245) A Study of Bempegaldesleukin (NKTR-214: BEMPEG) in Combination With Nivolumab Compared With the Investigator's Choice of a Tyrosine Kinase Inhibitor (TKI) Therapy (Either Sunitinib or Cabozantinib Monotherapy) for Advanced Metastatic Renal Cell Carcinoma (RCC)